Emergent BioSolutions: The path to re-emergence

Published on : Published by : Chris Frew

Emergent BioSolutions was arguably one batch away from being a pandemic hero. 
Just months after COVID-19 gripped the world, the Maryland-based life sciences company had locked in deals to manufacture two of the five leading Operation Warp Speed vaccine candidates. 
Shortly after Emergent had inked what eventually became a five-year deal worth at least $480 million with Johnson & Johnson to produce bulk drug substance for Janssen’s vaccine candidate, the U.S. government issued a $628 million task order to reserve capacity for a second OWS innovator — AstraZeneca. This resulted in Emergent signing an additional $261 million deal to make drug substances for the AstraZeneca-Oxford vaccine candidate. 

Miltenyi Biotec promotes Markus Weiss to Executive Vice President

Published on : Published by : BioBuzz Media

Markus Weiss, who in this role is responsible for supporting the North American Business Units and Divisions has 18 years of experience in operationalizing strategy, preserving and growing value, scaling culture as well as business transformations. He is experienced in divisional, regional and country level leadership roles in technology, life science, manufacturing, construction and financial services.

Altasciences Continues Building Expansion with Additional Location in Philadelphia

Published on : Published by : BioBuzz Media

Altasciences today announced the continued expansion of their formulation, manufacturing, and analytical services facilities in Philadelphia, PA. Altasciences, an integrated drug development solution company offering pharmaceutical and biotechnology companies worldwide a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services, launched a second building project to increase its capacity and meet the ever-growing needs of its clients.

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges

Biotech Boom Magnifies Biomanufacturing Capacity and Workforce Challenges
Published on : Published by : Steven Surdez

The ongoing pandemic response by the biopharma industry has been historic. Biotech companies and contract development and manufacturing organizations, along with the entire supply chain, have worked together to develop several SARS-CoV-2 vaccines, achieved Emergency Use Authorization(EUA) from the FDA, and began delivering desperately needed protection into people’s arms in less than a calendar year.

Why Philadelphia is Poised to Become a Top Cell and Gene Therapy Cluster

The Discovery Labs King of Prussia PA
Published on : Published by : Alex Keown

The Discovery Labs’ 2.4 million square foot site in King of Prussia, PA provides all the necessary ingredients to accelerate speed to market for cell and gene therapy innovators. The Center for Breakthrough Medicines is a cell and gene therapy contract development and manufacturing organization (CDMO) for plasmid DNA, viral vectors, and cellular therapy products and is located on-site.

5 Questions with Doug White, Senior Vice President, Devices Business Unit Head, Emergent BioSolutions

Published on : Published by : Andy Eckert

Doug White joined Emergent in 2017 and serves as head of the devices business unit. He previously served as vice president and general manager of Molecular Diagnostics & Women’s Health at Becton Dickenson Diagnostics. Before joining Becton Dickenson Diagnostics, he was chief executive officer of OpGen Inc.

In Conversation with Tia Lyles-Williams, Founder and CEO of LucasPye BIO and HelaPlex

Published on : Published by : Steven Surdez

Tia Lyles-Williams, the founder & CEO of LucasPye BIO (LPB) and HelaPlex, is on a mission to lower development and manufacturing costs for emerging life science companies while bringing greater diversity to the life science industry.

5 Questions with Mike O’Mara, VP of Industrial Business Services, Miltenyi Biotec

Published on : Published by : Andy Eckert

Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.

5 Questions with Nick Droste, Supervisor, Emergent BioSolutions Postfill Manufacturing Supervisor

Published on : Published by : Andy Eckert

Nick Droste is part of the postfill manufacturing team at the Emergent BioSolutions Baltimore Camden site, where he leads visual inspection operations for Emergent’s growing Contract Development Manufacturing and Organization (CDMO) efforts and in support of their new partnership with the Biomedical Advanced Research and Development Authority (BARDA) COVID-19 vaccine development operations.